To highlight some of the milestones on Andexamet. They will submit the PAS package later this summer. There will probably be a six month reviews time with the FDA. This leads them to expect GEN 2 approval in 1Q, 2019. They also have Europe and the CHMP opinion is schedules for 4Q, 2018. That is after a positive trend vote in the oral explanation. All of this and they will have ample GEN2 inventory upon approval. Nothing has changed here. On betrixaban, the launch will be similar to what has been seen with other thrombotics. When they launch into the hospital, there will be period of a burn in laying the groundwork at the hospital and the formularies. There are two step with the pharmacists at the hospitals. They start with the Drug and Therapeutics committees to get the drug on the formulary and then they need to go back and get on the electronic order set. It is a twp. step process. This has taken longer than they originally anticipated. It is a sequential process and 2018 is laying the groundwork for an inflection point in 2019 that will pull through sales. AndexXa is being sold into many of the same hospital that were involved in the ANEXXA-4 study. It is early as they just launched on May 23. The decision on which hospital to target was based on selecting some of the more robust Annexa-4 sites. Portola is of course very familiar with them and they know a lot about the drug. Thy expect level of use to parallel what was seen in the ANNEXA-4 study. With regard to the other hospitals the level 1 trauma centers and the stroke centers which have not used it before; the data is too small to extrapolate. However, the demand is outstripping the amount of drug that is available. Two years ago there were 116,000 hospital admissions for bleeding on apixaban and rivaroxaban. Perhaps 20% will be suitable for AndexXa-intracranial bleeds, unstable compartment bleeds. Portola must work carefully with the hospitals to make sure that they target with the hospitals to make sure that they are targeting the patients who will benefit the most. The experience so far is that hospitals in a very short period of time are seeing patients that they are treating. There are many hospital inquiring about the drug which they are not going to be able to supply until they get GEN-2 approval. These are large trauma centers and stroke centers. These will be prepared for when GEN2 inventory becomes available. They will expeditiously get them up to speed. They have manufactured enough GEN2 drug to treat thousands of patients. The level of stocking will vary at each hospital depending on their size. Right now Portola is controlling how much they can stock. This will change significantly when GEN 2 becomes available. In general, the hospitals have enough to treat two patients. Then as they treat, they will supply the next dose. With the larger hospitals they will stock in accordance with their needs. Smaller hospitals might see a patient per month and will stock accordingly. The first 30 to 40 sites were handpicked by Portola and half participated in the ANEEXA-4 trial. These are characterized by high factor Xa usage. Their use of the drug is almost exactly what Portola predicted. The next 600 hospitals they will be going after with GEN2. These are hospitals that see a lot of intracranial bleeds,